ImmunityBio Announces Completion of $470 Million Post …
https://www.businesswire.com/news/home/20211220005286/en/ImmunityBio-Announces-Completion-of-470-Million-Post-merger-Financing-to-Fund-Late-stage-Cancer-Clinical-Trials-Phase-3-of-COVID-T-Cell-Universal-Boost-Vaccine-Trial-and-Provides-Update-on-Bladder-Cancer-BLA-Filing
WebDec 20, 2021 · CULVER CITY, Calif.-- ( BUSINESS WIRE )--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, has successfully raised an aggregate $470 million of equity and debt financing...
DA: 72 PA: 66 MOZ Rank: 14